Cytochrome P450 CYP 2C19*2 Associated With Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome

摘要：

Introduction Clopidogrel, which irreversibly inhibits the adenosine diphosphate (ADP) platelet receptor P2Y12, has been widely used in preventing thromboembolic events in patients with acute coronary syndrome (ACS).However, a great number of patients under the treatment of clopidogrel still experience cardiovascular events.Various studies have demonstrated that the rate of clopidogrel resistance (CR) ranges 4.2-27.8％ ”1,2”.

作者: You-quan Wei Dian-gang Wang Hao Yang Heng Cao

作者单位: Department of Cardiology, The First Affiliated Hospital of Wannan Medical College, Wuhu, China Department of Cardiology, The Second People”s Hospital of Huangchuan County, Xinyang, China

会议类型: 国内会议

会议名称: 安徽省第十七次心血管病学术年会

会议地点: 合肥

会议语种:英文

页码: 80-83

在线出版日期: 2015-08-21（万方平台首次上网日期，不代表论文的发表时间）